Financials

	2024	2025
Net sales	4.05Cr 4.64Cr 3.78Cr 3.47Cr 6.52Cr 444.18Cr 6.67Cr 45Cr 18Cr 220.36Cr 17Cr 17Cr 758.43Cr	4.11Cr 4.71Cr 3.83Cr 3.53Cr 6.62Cr 450.89Cr 6.77Cr 45Cr 18Cr 223.69Cr 18Cr 17Cr 769.87Cr
Net income	71.55L 82.04L 66.75L 61.37L 1.15Cr 78Cr 1.18Cr 7.91Cr 3.09Cr 39Cr 3.08Cr 3.01Cr 134.02Cr	47.82L 54.84L 44.62L 41.02L 76.98L 52Cr 78.8L 5.29Cr 2.07Cr 26Cr 2.06Cr 2.01Cr 90Cr
Net Debt	-1.73Cr -1.98Cr -1.61Cr -1.48Cr -2.78Cr -189.28Cr -2.84Cr -19Cr -7.46Cr -94Cr -7.43Cr -7.27Cr -323.19Cr	-2.1Cr -2.41Cr -1.96Cr -1.8Cr -3.39Cr -230.77Cr -3.47Cr -23Cr -9.09Cr -114.49Cr -9.06Cr -8.86Cr -394.03Cr

Company Profile

Eurofins Cerep specializes in the pre-clinical research of drugs for the pharmaceutical industry. Export accounts for 88.2% of net sales.

Employees

Sector

Market Cap	8.22Cr 9.43Cr 7.67Cr 7.05Cr 13Cr 901.99Cr 14Cr 91Cr 36Cr 447.48Cr 35Cr 35Cr 1.54TCr	P/E 2024 *	-	P/E 2025	-
Enterprise Value	6.12Cr 7.02Cr 5.71Cr 5.25Cr 9.85Cr 671.22Cr 10Cr 68Cr 26Cr 332.99Cr 26Cr 26Cr 1.15TCr	EV / Sales 2024	2.02x	EV / Sales 2025	1.67x
Free-Float	4.22%	Yield 2024 *	-	Yield 2025	-

30/04	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02/25/02	Eurofins-Cerep SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
30/25/30	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
03/25/03	Eurofins-Cerep SA Reports Earnings Results for the Half Year Ended June 30, 2024	CI
30/24/30	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
30/23/30	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2022	CI
30/22/30	Eurofins-Cerep SA Reports Earnings Results for the Half Year Ended June 30, 2022	CI
12/22/12	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2021	CI
16/21/16	Global markets live: Daimler, GSK, Mattel
23/20/23	Eurofins Cerep : Launches PCR COVID-19 Self-Test In Germany, Spain	MT
24/20/24	Eurofins-Cerep Sa Reports Earnings Results for the Half Year Ended June 30, 2020	CI
30/18/30	Eurofins Cerep SA acquired KVI-Plusz.	CI
03/15/03	Eurofins Cerep SA and Jean-Louis Oger, along with the members of the current leadership of Bioaccess, completed the acquisition of a majority stake in Bioaccess S.A.	CI

18/25/18	Eurofins Cerep : annonce ses résultats du 1er semestre 2025	PU
13/23/13	Eurofins Cerep : annonce ses résultats 2022	PU

10/04	Eurofins Cerep : annonce ses résultats 2025
01/25/01	Eurofins Cerep : Rapport Financier Semestriel - Semestre clos le 30 juin 2025
09/25/09	Eurofins Cerep : Rapport annuel 2024
04/25/04	Eurofins Cerep : annonce ses résultats du 1er semestre 2023
04/25/04	Eurofins Cerep : annonce ses résultats 2024

Director	Title	Age	Since
Paul Ratcliffe CHM	Chairman	-	11/08/2023
Damien Vielliard BRD	Director/Board Member	-	23/05/2024
Rodolphe Simonot BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EUROFINS-CEREP	+0.01%	+4,900.50%	-	-	9.37Cr
LONZA GROUP AG	+2.61%	+1.91%	+1.70%	+13.91%	4.79TCr
REVOLUTION MEDICINES, INC.	-1.60%	-1.29%	+385.56%	+603.70%	3.91TCr
BEONE MEDICINES AG	-0.98%	+2.68%	+11.10%	+45.34%	3.67TCr
IQVIA HOLDINGS INC.	+1.90%	+22.79%	+25.18%	+9.47%	4.05TCr
CELLTRION, INC.	+1.47%	+4.90%	+6.48%	+43.52%	2.8TCr
ASCENDIS PHARMA A/S	-0.94%	-1.23%	-	-	1.68TCr
MEDPACE HOLDINGS, INC.	+2.44%	+10.02%	+29.11%	+129.56%	1.59TCr
EUROFINS SCIENTIFIC SE	+0.18%	-1.46%	+4.92%	+10.14%	1.36TCr
ICON PUBLIC LIMITED COMPANY	-1.14%	+6.94%	-6.05%	-29.33%	1.38TCr
Average	+0.39%	+4.66%	+57.25%	+103.29%	2.8TCr
Weighted average by Cap.	+0.61%	+5.06%	+73.07%	+124.52%